Personalizing Deep Brain Stimulation Therapy for Parkinson's Disease With Whole-Brain MRI Radiomics and Machine Learning

• Published in: Curēus (Palo Alto, CA) CA), 2024-05, Vol.16 (5), p.e59915
• Main Authors: Haliasos, Nikolaos, Giakoumettis, Dimitrios, Gnanaratnasingham, Prathishta, Low, Hu Liang, Misbahuddin, Anjum, Zikos, Panagiotis, Sakkalis, Vangelis, Cleo, Spanaki, Vakis, Antonios, Bisdas, Sotirios
• Format: Article
• Language: English
• Subjects: Deep brain stimulation; Healthcare Technology; Machine learning; Mental disorders; Neurosurgery; Open source software; Parkinson's disease; Patients; Quality of life; Radiology; Radiomics; Surgery
• ISSN: 2168-8184; 2168-8184
• DOI: 10.7759/cureus.59915

Background Deep brain stimulation (DBS) is a well-recognised treatment for advanced Parkinson's disease (PD) patients. Structural brain alterations of the white matter can correlate with disease progression and act as a biomarker for DBS therapy outcomes. This study aims to develop a machine learning-driven predictive model for DBS patient selection using whole-brain white matter radiomics and common clinical variables. Methodology A total of 120 PD patients underwent DBS of the subthalamic nucleus. Their therapy effect was assessed at the one-year follow-up with the Unified Parkinson's Disease Rating Scale-part III (UPDRSIII) motor component. Radiomics analysis of whole-brain white matter was performed with PyRadiomics. The following machine learning methods were used: logistic regression (LR), support vector machine, naïve Bayes, K-nearest neighbours, and random forest (RF) to allow prediction of clinically meaningful UPRDSIII motor response before and after. Clinical variables were also added to the model to improve accuracy. Results The RF model showed the best performance on the final whole dataset with an area under the curve (AUC) of 0.99, accuracy of 0.95, sensitivity of 0.93, and specificity of 0.97. At the same time, the LR model showed an AUC of 0.93, accuracy of 0.88, sensitivity of 0.84, and specificity of 0.91. Conclusions Machine learning models can be used in clinical decision support tools which can deliver true personalised therapy recommendations for PD patients. Clinicians and engineers should choose between best-performing, less interpretable models vs. most interpretable, lesser-performing models. Larger clinical trials would allow to build trust among clinicians and patients to widely use these AI tools in the future.